Athira Pharma ATHA 深 滬
等待開盤 10-29 09:30:00 美东时间
4.23
+0.080
+1.93%
華盛通- 最 高4.23
- 今 開4.17
- 成交量 2.12万股
- 最 低 4.05
- 昨 收 4.15
- 總市值 1668.27万
- 52周最高 8.264
- 市盈率 靜 --
- 換手率 0.54%
- 52周最低 2.195
- 委 比 -57.04%
- 總股本 394.39万
- 歷史最高 347.90
- 量 比 0.55
- 振 幅 4.34%
- 歷史最低 2.195
- 每 手 1
- 風險率 1.24%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Athena Gold to Participate in Munich Mining Conference 2025
An update from Athena Gold ( ($TSE:ATHA) ) is now available. Athena Gold Corpor...
09-30 19:46
Athira Pharma Has Been Granted A U.S. Patent "Methods of treating neurodegenerative disease (including dementia, Alzheimer's disease, and Parkinson's disease) with substituted n-hexanoic-l-tyrosine-l-isoleucine-(6)-aminohexanoic amide analogues". https://t.co/NSHLVnfwcm.
https://ppubs.uspto.gov/pubwebapp/external.html?q=(12421276).pn
09-24 04:00
Athira Pharma To Implement 10-For-1 Reverse Stock Split Following Shareholder Approval At May 2025 Annual Meeting
Athira Pharma, Inc. ("Athira" or "Company") (NASDAQ:ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that it
09-11 21:03
Athira Pharma Presents ATH-1105 Phase 1 Trial Results at ALS Nexus 2025
Athira Pharma presented Phase 1 trial results for ATH-1105, a novel small molecule targeting neurodegenerative diseases like ALS, at the ALS Nexus 2025 conference. The trial, involving 80 healthy volunteers, demonstrated favorable safety, tolerability, and CNS penetration, supporting further development of the drug candidate. ATH-1105 aims to modulate the neurotrophic HGF system to restore neuronal health. The company highlighted the potential of...
08-14 11:00
Athira Pharma Q2 EPS $(0.18), Inline
Athira Pharma (NASDAQ:ATHA) reported quarterly losses of $(0.18) per share which met the analyst consensus estimate. This is a 74.29 percent increase over losses of $(0.70) per share from the same period last year.
08-08 04:55
Athira Pharma Reports Second Quarter 2025 Financial Results and Provides Business Update
<p style="font-family: Arial, sans-serif;"> Athira Pharma reported positive Phase 1 clinical trial results for ATH-1105, showing favorable safety, tolerability, and CNS penetration, supporting its development for ALS. The company paused fosgonimeton's development and is exploring strategic alternatives. Financials showed reduced cash, lower R&D and G&A expenses, and a narrowed net loss. </p>
08-07 20:05
Yatharth Hospital Appoints New Statutory Auditors
Yatharth Hospital and Trauma Care Services Limited ( ($IN:YATHARTH) ) has provi...
08-06 06:23
Yatharth Hospital Announces Auditor Resignation
Yatharth Hospital and Trauma Care Services Limited ( ($IN:YATHARTH) ) just unve...
08-06 02:12
Athena Gold Boosts Visibility with New Marketing Agreements
Athena Gold ( ($TSE:ATHA) ) has provided an update. Athena Gold Corporation has...
07-04 22:07
ATHA Energy Unveils Promising Uranium Discoveries in Angikuni Basin
Atha Energy Corp. ( ($TSE:SASK) ) has provided an announcement. ATHA Energy Cor...
06-24 20:11
